0001558370-24-004285.txt : 20240328 0001558370-24-004285.hdr.sgml : 20240328 20240328172713 ACCESSION NUMBER: 0001558370-24-004285 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240328 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240328 DATE AS OF CHANGE: 20240328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nutex Health, Inc. CENTRAL INDEX KEY: 0001479681 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 113363609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41346 FILM NUMBER: 24800623 BUSINESS ADDRESS: STREET 1: 6030 S. RICE AVE. STREET 2: SUITE C CITY: HOUSTON STATE: TX ZIP: 77081 BUSINESS PHONE: (713) 660-0557 MAIL ADDRESS: STREET 1: 6030 S. RICE AVE. STREET 2: SUITE C CITY: HOUSTON STATE: TX ZIP: 77081 FORMER COMPANY: FORMER CONFORMED NAME: Clinigence Holdings, Inc. DATE OF NAME CHANGE: 20191113 FORMER COMPANY: FORMER CONFORMED NAME: iGambit, Inc. DATE OF NAME CHANGE: 20091230 8-K 1 nutx-20240328x8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 28, 2024

NUTEX HEALTH INC.

(Exact name of registrant as specified in its charter)


Delaware	001-41346	11-3363609
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

‎6030 S. Rice Ave, Suite C, Houston, Texas 77081

(Address of principal executive offices) (zip code)

‎(713) 660-0557‎

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbols(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	NUTX	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.‎ Results of Operations and Financial Condition

On March 28, 2024, Nutex Health Inc. (the “Company”) announced its financial and operating results for the quarter ending December 31, 2023. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


Exhibit No.	Description of Exhibit
99.1	Press Release dated March 28, 2024
104	Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

THE INFORMATION CONTAINED IN ITEM 2.02 OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



	Date: March 28, 2024
	Nutex Health Inc.

	By: /s/ Jon C. Bates
	Jon C. Bates
	Chief Financial Officer

EX-99 2 nutx-20240328xex99.htm EX-99

NUTEX HEALTH reports fourth quarter and Full YEAR 2023 financial results

●

Total revenue of $247.6 million for the year ended 2023 vs $219.3 Million in 2022, an increase of 13%

●

hospital division operating income of $36.3 million for Year Ended 2023 VS $15.0 million in 2022, an increase of 142%

●

Net cash from operating activities of $1.3 million for the YEAR ended 2023

●

Continued focus on INCREASED CASH FLOW THROUGH REDUCTION IN OPERATING EXPENSES AND PORTFOLIO OPTIMIZATION

HOUSTON, TX − (PRNewswire) – MARCH 28, 2024 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 20 state-of-the-art micro hospitals in eight states and primary care-centric, risk-bearing physician networks, today announced fourth quarter and fiscal year 2023 financial results for the twelve months ended December 31, 2023.

Financial Highlights for the Three Months Ended December 31, 2023:

●

Total revenue of $69.7 million as compared to total revenue of $53.7 million for the three months ended December 31, 2022, an increase of approximately 30%.

●

Net loss attributable to Nutex Health Inc. of $31.6 million (including a non-cash asset impairment charge of $29.1 million and a $1.1 million goodwill impairment charge for hospital closures) as compared to net loss attributable to Nutex Health Inc. of $14.8 million for the three months ended December 31, 2022.

●

Adjusted EBITDA of $3.1 million as compared to Adjusted EBITDA of negative $5.9 million for the three months ended December 31, 2022.

Financial Highlights for the Year Ended December 31, 2023:

●

Total revenue of $247.6 million as compared to total revenue of $219.3 million for the year ended December 31, 2022.

●

Net loss attributable to Nutex Health Inc. of $45.8 million (including a non-cash asset impairment charge of $29.1 million and a $1.1 million goodwill impairment charge for hospital closures) as compared to net loss attributable to Nutex Health Inc. of $424.8 million (including a non-cash goodwill impairment charge of $398.1 million) for the year ended December 31, 2022.

●

Adjusted EBITDA of $10.8 million as compared to Adjusted EBITDA of $12.6 million for the year ended December 31, 2022.

●

Net cash from operating activities of $1.3 million.

●

As of December 31, 2023, the Company had total assets of $398.2 million, including cash and cash equivalents of $22.0 million.

Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

“We are pleased to report 13% revenue growth, $10.8 million of Adjusted EBITDA and a 142% increase in hospital division operating income to $36.3 million in 2023,” stated Jon Bates, Chief Financial Officer of Nutex Health.

“We had a solid 4^th Quarter in 2023. In January of 2024, our management team and Board of Directors initiated a streamlined strategic plan that included a targeted reduction in annual cash operating expenses as well as a more focused allocation of resources and portfolio optimization. Some of these initiatives have already been executed while others are in the process of being implemented. Our goal for 2024 is to continue to be the leader and innovator in our industry, and to provide a very unique platform for selected growth opportunities,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

Page 1 of 8

“We are intensely focused on our goal to deliver profitability on a net income basis to our investors. We believe that we are well positioned to improve our financial performance over the medium and long-term,” stated Warren Hosseinion, M.D., President of Nutex Health.

For more details on the Company’s Fourth Quarter and Fiscal Year 2023 financial results, please refer to our Annual Report on Form 10-K filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.

Page 2 of 8

NUTEX HEALTH INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)


	December 31,
	2023		2022
Assets
Current assets:
Cash and cash equivalents	$	22,002,056	$	34,255,264
Accounts receivable		58,624,301		57,777,386
Accounts receivable - related parties		4,152,068		538,183
Inventories		3,390,584		3,533,285
Prepaid expenses and other current assets		2,679,394		1,869,806
Total current assets		90,848,403		97,973,924
Property and equipment, net		81,387,649		82,094,352
Operating right-of-use assets		11,853,082		20,466,632
Financing right-of-use assets		176,146,329		192,591,624
Intangible assets, net		20,512,636		21,191,390
Goodwill, net		17,066,263		17,010,637
Other assets		431,135		423,426

Total assets	$	398,245,497	$	431,751,985

Liabilities and Equity
Current liabilities:
Accounts payable	$	18,899,196	$	23,614,387
Accounts payable - related parties		6,382,197		3,915,661
Lines of credit		3,371,676		2,623,479
Current portion of long-term debt		10,808,721		12,546,097
Operating lease liabilities, current portion		1,579,987		1,703,014
Financing lease liabilities, current portion		4,315,979		4,219,518
Accrued expenses and other current liabilities		12,955,296		6,240,813
Total current liabilities		58,313,052		54,862,969
Long-term debt, net		26,314,733		23,051,152
Operating lease liabilities, net		15,479,639		19,438,497
Financing lease liabilities, net		213,886,213		203,619,756
Deferred tax liabilities		5,145,754		10,452,211
Total liabilities		319,139,391		311,424,585

Commitments and contingencies (Note 10)

Equity:
Common stock, $0.001 par value; 950,000,000 shares authorized; 676,679,911 and 650,223,840 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively		676,680		650,224
Additional paid-in capital		469,849,049		458,498,402
Accumulated deficit		(409,072,539)		(363,285,925)
Nutex Health Inc. equity		61,453,190		95,862,701
Noncontrolling interests		17,652,916		24,464,699
Total equity		79,106,106		120,327,400

Total liabilities and equity	$	398,245,497	$	431,751,985

Page 3 of 8

NUTEX HEALTH INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	Three months ended December 31				Year ended December 31
	2023		2022		2023		2022
Revenue:
Hospital division	$	62,585,167	$	46,532,019	$	218,070,397	$	198,508,245
Population health management division		7,084,306		7,192,054		29,575,919		20,786,061
Total revenue		69,669,473		53,724,073		247,646,316		219,294,306

Operating costs and expenses:
Payroll		28,807,419		26,466,650		108,377,938		111,785,110
Contract services		14,377,128		9,809,286		42,349,982		35,913,441
Medical supplies		3,402,926		2,791,779		14,151,140		12,118,893
Insurance expense		-		2,284,377		-		-
Depreciation and amortization		4,682,724		3,271,861		17,591,572		13,131,374
Other		5,185,964		8,569,796		30,401,513		30,923,750
Total operating costs and expenses		56,456,161		53,193,749		212,872,145		203,872,568

Gross profit		13,213,312		530,324		34,774,171		15,421,738

Corporate and other costs:
Facilities closing costs		-		-		217,266		-
Acquisition costs		-		-		43,464		3,885,666
Stock-based compensation		637,159		-		2,835,971		189,581
Impairment of assets		29,082,203		-		29,082,203		-
Impairment of goodwill		1,139,297		-		1,139,297		398,135,038
General and administrative expenses		8,499,550		6,309,235		33,229,718		19,810,607
Total corporate and other costs		39,358,209		6,309,235		66,547,919		422,020,892

Operating income (loss)		(26,144,897)		(5,778,911)		(31,773,748)		(406,599,154)

Interest expense, net		4,236,553		2,862,071		16,317,869		12,490,260
Other expense (income)		328,461		212,426		399,182		559,299
Income (loss) before taxes		(30,709,911)		(8,853,408)		(48,490,799)		(419,648,713)

Income tax expense (benefit)		(2,998,554)		1,805,176		(5,067,084)		13,090,905

Net income (loss)		(27,711,357)		(10,658,584)		(43,423,715)		(432,739,618)

Less: net income (loss) attributable to noncontrolling interests		3,906,540		4,093,593		2,362,899		(7,959,172)

Net income (loss) attributable to Nutex Health Inc.	$	(31,617,897)	$	(14,752,177)	$	(45,786,614)	$	(424,780,446)

Earnings (loss) per common share
Basic		(0.05)		(0.02)		(0.07)		(0.67)
Diluted		(0.05)		(0.02)		(0.07)		(0.67)

Page 4 of 8

NUTEX HEALTH INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Year ended December 31,
	2023		2022		2021
Cash flows from operating activities:
Net income (loss)	$	(43,423,715)	$	(432,739,618)	$	168,525,285
Adjustment to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization		17,591,572		13,131,374		7,662,464
Debt accretion expense		1,209,981		1,952,829		50,273
Impairment of assets		29,082,203		-		-
Impairment of goodwill		1,139,297		398,135,038		-
Stock-based compensation expense		2,835,971		189,581		-
Rescission of warrant exercise expense		-		561,651		-
Other income - gain on PPP loan forgiveness		-		-		(5,546,597)
Deferred tax expense (benefit)		(5,707,323)		4,996,209		-
(Gain) loss on lease termination		58,210		-		(109,494)
Non-cash lease expense		131,582		64,143		97,578
Changes in operating assets and liabilities:
Accounts receivable		(969,761)		56,622,133		(5,392,614)
Accounts receivable - related party		(3,613,885)		1,454,934		(1,229,940)
Inventories		142,701		(719,107)		(1,088,489)
Prepaid expenses and other current assets		(817,297)		(1,419,139)		(233,114)
Accounts payable		(4,715,101)		10,018,100		6,365,978
Accounts payable - related party		2,466,536		(329,155)		(97,985)
Accrued expenses and other current liabilities		5,845,481		(1,311,865)		4,429,141
Net cash from operating activities		1,256,452		50,607,108		173,432,486

Cash flows from investing activities:
Acquisitions of property and equipment		(9,496,832)		(14,632,414)		(36,926,591)
Acquired cash in reverse acquisition with Clinigence		-		12,716,228		-
Payments for acquisitions of businesses, net of cash acquired		(703,893)		-		-
Cash related to deconsolidation of Real Estate Entities		(1,039,157)		(2,421,212)		(48,853)
Net cash from investing activities		(11,239,882)		(4,337,398)		(36,975,444)

Cash flows from financing activities:
Proceeds from lines of credit		2,340,911		2,623,479		-
Proceeds from notes payable		16,952,905		815,881		19,614,372
Proceeds from convertible notes		4,909,864		-		-
Repayments of lines of credit		(1,592,714)		(72,055)		(864,659)
Repayments of notes payable		(16,479,512)		(7,237,094)		(20,715,235)
Repayments of finance leases		(3,484,683)		(1,721,224)		(1,255,486)
Payment of debt issuance costs		-		-		(47,875)
Rescission of warrant exercise		-		(588,042)		-
Common stock issued for exercise of warrants		-		4,119,141		-
Common stock issued for exercise of options		-		644,974		-
Members' contributions		298,032		4,513,867		21,753,773
Members' distributions		(5,214,581)		(51,231,657)		(144,337,923)
Net cash from financing activities		(2,269,778)		(48,132,730)		(125,853,033)
Net change in cash and cash equivalents		(12,253,208)		(1,863,020)		10,604,009
Cash and cash equivalents - beginning of the year		34,255,264		36,118,284		25,514,275
Cash and cash equivalents - end of the year	$	22,002,056	$	34,255,264	$	36,118,284

Page 5 of 8

Non-GAAP Financial Measures (Unaudited)

Adjusted EBITDA. Adjusted EBITDA is used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe Adjusted EBITDA is useful because it allows us to more effectively evaluate our operating performance.

We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense, any acquisition-related costs and impairments. A reconciliation of net income to Adjusted EBITDA is included below. Adjusted EBITDA is not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies.


	Year ended December 31,
	2023		2022		2021
Reconciliation of net income (loss) attributable to Nutex Health Inc. to Adjusted EBITDA:
Net income (loss) attributable to Nutex Health Inc.	$	(45,786,614)	$	(424,780,446)	$	132,593,328
Depreciation and amortization		17,591,572		13,131,374		7,662,464
Interest expense, net		16,317,869		12,490,260		6,196,026
Income tax expense		(5,067,084)		13,090,905		965,731
Allocation to noncontrolling interests		(5,546,263)		(4,837,514)		(5,751,066)
EBITDA		(22,490,520)		(390,905,421)		141,666,483
Facility closing costs		217,266		-		-
Acquisition costs		43,464		3,885,666		3,553,716
Stock-based compensation		2,835,971		189,581		-
Rescission of warrant exercise		-		1,243,059		-
Impairment of assets		29,082,203		-		-
Impairment of goodwill		1,139,297		398,135,038		-
Adjusted EBITDA	$	10,827,681	$	12,547,923	$	145,220,199


	Three months ended		Three months ended
	December 31, 2023		December 31, 2022
	Unaudited		Unaudited
Reconciliation of net income (loss) attributable to Nutex Health Inc. to Adjusted EBITDA:
Net loss attributable to Nutex Health Inc.	$	(31,617,897)	$	(14,752,177)
Depreciation and amortization		4,682,724		3,271,861
Interest expense, net		4,236,553		2,862,071
Income tax expense		(2,998,554)		1,805,176
Allocation to noncontrolling interests		(2,045,390)		(392,290)
EBITDA		(27,742,564)		(7,205,359)
Stock-based compensation		637,159		54,166
Rescission of warrant exercise		-		1,243,059
Impairment of assets		29,082,203		-
Impairment of goodwill		1,139,297		-
Adjusted EBITDA	$	3,116,095	$	(5,908,134)

Page 6 of 8

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 20 facilities in 8 states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently.

Page 7 of 8

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2023 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

FOR ADDITIONAL INFORMATION:

Nutex Health, Inc.

Jennifer Smith Rodriguez – Investor Relations

investors@nutexhealth.com

– Media Contact

jsmith@nutexhealth.com

Page 8 of 8

GRAPHIC 3 nutx-20240328xex99001.jpg GRAPHIC begin 644 nutx-20240328xex99001.jpg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end EX-101.SCH 4 nutx-20240328.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 nutx-20240328_def.xml EX-101.DEF EX-101.LAB 6 nutx-20240328_lab.xml EX-101.LAB Document and Entity Information [Abstract] Document Information [Table] Document Information [Line Items] Document Type Document Period End Date Entity Registrant Name Entity Incorporation, State or Country Code Entity File Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Adress Line Two Entity Address, City or Town Entity Address State Or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity Emerging Growth Company Entity Central Index Key Amendment Flag EX-101.PRE 7 nutx-20240328_pre.xml EX-101.PRE XML 9 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Mar. 28, 2024
Document and Entity Information [Abstract]
Document Type	8-K
Document Period End Date	Mar. 28, 2024
Entity Registrant Name	NUTEX HEALTH INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-41346
Entity Tax Identification Number	11-3363609
Entity Address, Address Line One	6030 S. Rice Ave
Entity Address, Adress Line Two	Suite C
Entity Address, City or Town	Houston
Entity Address State Or Province	TX
Entity Address, Postal Zip Code	77081
City Area Code	713
Local Phone Number	660-0557
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	NUTX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001479681
Amendment Flag	false

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://nutexhealth.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports nutx-20240328.xsd nutx-20240328_def.xml nutx-20240328_lab.xml nutx-20240328_pre.xml nutx-20240328x8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nutx-20240328x8k.htm": { "nsprefix": "nutx", "nsuri": "http://nutexhealth.com/20240328", "dts": { "schema": { "local": [ "nutx-20240328.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "nutx-20240328_def.xml" ] }, "labelLink": { "local": [ "nutx-20240328_lab.xml" ] }, "presentationLink": { "local": [ "nutx-20240328_pre.xml" ] }, "inline": { "local": [ "nutx-20240328x8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_3_28_2024_To_3_28_2024_BtIOFftWyEGpMXyAhEhsCg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240328x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_3_28_2024_To_3_28_2024_BtIOFftWyEGpMXyAhEhsCg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240328x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001558370-24-004285-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-004285-xbrl.zip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end XML 19 nutx-20240328x8k_htm.xml IDEA: XBRL DOCUMENT 0001479681 2024-03-28 2024-03-28 0001479681 false 8-K 2024-03-28 NUTEX HEALTH INC. DE 001-41346 11-3363609 6030 S. Rice Ave Suite C Houston TX 77081 713 660-0557 false false false false Common Stock, $0.001 par value NUTX NASDAQ false